ADMA Biologics Inc

NASDAQ:ADMAUnited States

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Contact Information

Headquarters

C/O Adma Biologics Inc., 465 State Route 17RAMSEY, NJ, United States 07446

Phone

201-478-5552

Fax

201-478-5553

Executives

Independent Chairman of the Board

Steven Elms

President, Chief Executive Officer, Co-Founder, Interim Chief Financial Officer, Director

Adam Grossman

Vice Chairman of the Board, Co-Founder

Jerrold Grossman

Chief Operating Officer, Senior Vice President - Compliance

Kaitlin Kestenberg

Director

Alison Finger